Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30178974 | 1.00 | KDM4E (0.41) | KDM4ETDP1CYP2D6ADRA2AADRA1A | |
| SCHEMBL21673459 | 1.00 | KDM4E (0.41) | KDM4ETDP1CYP2D6ADRA2AADRA1A | |
| SCHEMBL20855486 | 0.85 | CYP2D6 (0.49) | KDM4ETDP1CYP2D6ADRA2AADRA1A | |
| SCHEMBL143912 | 0.85 | CYP2D6 (0.49) | KDM4ETDP1CYP2D6ADRA2AADRA1A | |
| SCHEMBL30626962 | 0.84 | LPAR1 (0.49) | KDM4ETDP1POLBGAAGFER | |
| SCHEMBL12806459 | 0.84 | LPAR1 (0.49) | KDM4ETDP1POLBGAAGFER | |
| Hydrochloric Acid SCHEMBL20855876 | 0.83 | MEN1 (0.50) | KDM4ETDP1CYP2D6ADRA2AADRA1A | |
| Hydrochloric Acid SCHEMBL3538526 | 0.83 | MEN1 (0.50) | KDM4ETDP1CYP2D6ADRA2AADRA1A | |
| SCHEMBL16564328 | 0.81 | LPAR1 (0.43) | KDM4ETDP1GAA | |
| SCHEMBL7947311 | 0.78 | TSHR (0.42) | KDM4ETDP1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1965785-A1 | COMPOUNDS WITH MEDICINAL EFFECTS DUE TO INTERACTION WITH THE GLUCOCORTICOID RECEPTOR | N.V. Organon (NL) | 2008-09-10 | — | — | EP | disclosed |
| US-20070149577-A1 | Compounds with medicinal effects due to interaction with the glucocorticoid receptor | N.V. ORGANON (NL) | 2007-06-28 | — | — | US | disclosed |
| WO-2007071638-A1 | COMPOUNDS WITH MEDICINAL EFFECTS DUE TO INTERACTION WITH THE GLUCOCORTICOID RECEPTOR | N.V. ORGANON (NL) | 2007-06-28 | — | — | WO | disclosed |
| US-6093851-A | N-(α-alkylbenzylidene)-α-phenylalkylamine, its use and process for producing the same and process for producing intermediate therefor | SUMITOMO CHEMICAL COMPANY, LTD. (JP) | 2000-07-25 | — | — | US | disclosed |
| EP-0735018-B1 | N-(alpha-alkylbenzylidene)-alpha-phenylalkylamine, its use and process for producing the same and process for producing intermediate therefor | SUMITOMO CHEMICAL CO (JP) | 1999-07-21 | — | — | EP | disclosed |
| US-5739401-A | N-(α-alkylbenzylidene)-α-phenylalkylamine, its use and process for producing the same and process for producing intermediate therefor | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1998-04-14 | — | — | US | disclosed |
| EP-0735018-A1 | N-(alpha-alkylbenzylidene)-alpha-phenylalkylamine, its use and process for producing the same and process for producing intermediate therefor | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 1996-10-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149577-A1 | Compounds with medicinal effects due to interaction with the glucocorticoid receptor | NR3C1, NR3C2, MC2R | KDM4E 2478/4885TDP1 3950/4885CYP2D6 218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.